Alcohol use disorder (AUD) is a major global public health issue, affecting more than 28 million adults in the United States ...

Teens who have parental permission to drink are more likely to develop unhealthy relationships with alcohol as adults, a ...

There are early and suggestive data that GLP-1 drugs reduce alcohol cravings. A large cohort of people with alcohol use ...

Study finds letting teens drink at home may lead to heavier alcohol use 03:59. Some parents might think that letting their ...

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.

A phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving with low-dose semaglutide. HealthDay News — Low-dose semaglutide seems to reduce craving and certain ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

March 13 (Reuters) - Altimmune (ALT.O), opens new tab said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol ...

Clearmind Medicine Inc. initiates a Phase I/IIa trial for CMND-100, targeting Alcohol Use Disorder in multiple research institutions. Clearmind Medicine Inc. has launched its Phase I/IIa clinical ...

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?